S. Silvente-Poirot

发表

The tumor‐suppressor cholesterol metabolite, dendrogenin A, is a new class of LXR modulator activating lethal autophagy in cancers

M. Poirot, S. Silvente-Poirot, 2018, Biochemical pharmacology.

Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM‐mediated autophagy, cell differentiation and death

F. Dalenc, M. Poirot, S. Silvente-Poirot, 2017, Biochemical pharmacology.

Dendrogenin A: A Mammalian Metabolite of Cholesterol with Tumor Suppressor and Neurostimulating Properties.

F. Dalenc, M. Poirot, S. Silvente-Poirot, 2015, Current medicinal chemistry.

Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands

M. Poirot, S. Silvente-Poirot, P. de Medina, 2010, Proceedings of the National Academy of Sciences.

Auraptene Is an Inhibitor of Cholesterol Esterification and a Modulator of Estrogen Receptors

K. Bystricky, M. Poirot, S. Silvente-Poirot, 2010, Molecular Pharmacology.

Molecular Characterization of the Microsomal Tamoxifen Binding Site*

M. Oulad-Abdelghani, G. Favre, M. Poirot, 2004, Journal of Biological Chemistry.

Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins[S]

Bernard Monsarrat, Alexandre Stella, B. Monsarrat, 2010, Journal of Lipid Research.

Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition)

Sangeeta Khare, Xin Qi, Ying Wang, 2016 .

Ligand-induced Internalization of Cholecystokinin Receptors

N. Tarasova, S. Silvente-Poirot, S. Wank, 1997, The Journal of Biological Chemistry.

Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism

J. Bertrand-Michel, M. Poirot, S. Silvente-Poirot, 2009, Cell Death and Differentiation.

Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion

M. Poirot, S. Silvente-Poirot, P. de Medina, 2009, Journal of Lipid Research.

Cholesterol-5,6-epoxides: chemistry, biochemistry, metabolic fate and cancer.

M. Poirot, S. Silvente-Poirot, 2013, Biochimie.

Evidence for a Direct Interaction between the Penultimate Aspartic Acid of Cholecystokinin and Histidine 207, Located in the Second Extracellular Loop of the Cholecystokinin B Receptor*

B. Maigret, N. Vaysse, S. Silvente-Poirot, 1999, The Journal of Biological Chemistry.

Quantitative analysis of the tumor suppressor dendrogenin A using liquid chromatography tandem mass spectrometry.

M. Poirot, S. Silvente-Poirot, J. Leignadier, 2017, Chemistry and physics of lipids.

Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosome‐enriched vesicles

V. Lotteau, M. Record, Kévin Carayon, 2022, Journal of extracellular vesicles.

Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation.

M. Poirot, S. Silvente-Poirot, J. Delord, 2010, Bioorganic & medicinal chemistry.

Synthesis, characterization and in vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting.

M. Poirot, S. Silvente-Poirot, E. Benoist, 2010, European journal of medicinal chemistry.

Flavonoids differentially modulate liver X receptors activity—Structure-function relationship analysis

M. Makishima, G. Lizard, M. Poirot, 2019, Journal of Steroid Biochemistry and Molecular Biology.

Dendrogenin A drives LXR to trigger lethal autophagy in cancers

M. Record, Kévin Carayon, L. Ligat, 2017, Nature Communications.

Cholesterol metabolism and cancer: the good, the bad and the ugly.

M. Poirot, S. Silvente-Poirot, 2012, Current opinion in pharmacology.

Dendrogenin A and B two new steroidal alkaloids increasing neural responsiveness in the deafened guinea pig

M. Ulfendahl, M. Poirot, S. Silvente-Poirot, 2015, Front. Aging Neurosci..

The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells

M. Poirot, S. Silvente-Poirot, B. Payre, 2019, The Journal of Steroid Biochemistry and Molecular Biology.

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo

M. Record, C. Récher, M. Poirot, 2020, Cancers.

Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia

C. Récher, M. Poirot, S. Silvente-Poirot, 2020, Cancers.

Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.

B. Maigret, L. Pradayrol, S. Silvente-Poirot, 2002, Pharmacology & toxicology.

The Biologically Crucial C Terminus of Cholecystokinin and the Non-peptide Agonist SR-146,131 Share a Common Binding Site in the Human CCK1 Receptor

B. Maigret, L. Pradayrol, S. Silvente-Poirot, 2002, The Journal of Biological Chemistry.

Arginine 197 of the cholecystokinin‐A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin

B. Maigret, N. Vaysse, S. Silvente-Poirot, 2008, Protein science : a publication of the Protein Society.

Chemistry, biochemistry, metabolic fate and mechanism of action of 6-oxo-cholestan-3β,5α-diol (OCDO), a tumor promoter and cholesterol metabolite.

F. Dalenc, M. Poirot, S. Silvente-Poirot, 2018, Biochimie.

Technical note: Hapten synthesis, antibody production and development of an enzyme-linked immunosorbent assay for detection of the natural steroidal alkaloid Dendrogenin A.

G. Delsol, M. Poirot, S. Silvente-Poirot, 2013, Biochimie.

A fast UPLC–HILIC method for an accurate quantiﬁcation of dendrogenin A in human tissues

F. Dalenc, M. Poirot, S. Silvente-Poirot, 2019, The Journal of Steroid Biochemistry and Molecular Biology.

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

Mark R. Marten, Erinna F. Lee, Dana L. Miller, 2021, Autophagy.

Oxysterols: An expanding family of structurally diversified bioactive steroids

M. Poirot, S. Silvente-Poirot, 2019, The Journal of Steroid Biochemistry and Molecular Biology.

Mutation of Asn-391 within the Conserved NPXXY Motif of the Cholecystokinin B Receptor Abolishes Gq Protein Activation without Affecting Its Association with the Receptor*

A. Kowalski-Chauvel, L. Pradayrol, N. Vaysse, 2000, The Journal of Biological Chemistry.

Cholesterol epoxide hydrolase and cancer.

M. Poirot, S. Silvente-Poirot, 2012, Current opinion in pharmacology.

The third intracellular loop of the rat and mouse cholecystokinin-A receptors is responsible for different patterns of gene activation.

S. Silvente-Poirot, C. Escrieut, D. Fourmy, 2000, Molecular pharmacology.

High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor

L. Pradayrol, L. Buscail, M. Poirot, 2003, Oncogene.

Natural and semisynthetic oxyprenylated aromatic compounds as stimulators or inhibitors of melanogenesis.

M. Poirot, S. Silvente-Poirot, S. Genovese, 2019, Bioorganic chemistry.

Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands.

M. Record, F. Dalenc, M. Poirot, 2011, Chemistry and physics of lipids.

HPLC Analysis and Skin Whitening Effects of Umbelliprenin-containing Extracts of Anethum Graveolens, Pimpinella Anisum, and Ferulago Campestris

M. Poirot, S. Silvente-Poirot, P. de Medina, 2019, Molecules.

Bryonolic Acid Blocks Cancer Cell Clonogenicity and Invasiveness through the Inhibition of Fatty Acid: Cholesteryl Ester Formation

R. Owen, M. Poirot, S. Silvente-Poirot, 2018, Biomedicines.

Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds

K. Bystricky, M. Poirot, S. Silvente-Poirot, 2016, Front. Oncol..

Cholesterol and Cancer, in the Balance

M. Poirot, S. Silvente-Poirot, Sandrine Silvente-Poirot, 2014, Science.

5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of tamoxifen in breast cancer cells.

V. Jordan, M. Record, F. Dalenc, 2013, Biochemical pharmacology.

Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties

M. Lacroix-Triki, B. Hammock, C. Morisseau, 2013, Nature Communications.

Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.

M. Poirot, S. Silvente-Poirot, P. de Medina, 2009, Journal of medicinal chemistry.

Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells

G. Favre, M. Poirot, S. Silvente-Poirot, 2004, Journal of Pharmacology and Experimental Therapeutics.

The peripheral cholecystokinin receptors.

N. Vaysse, S. Silvente-Poirot, D. Fourmy, 1993, European journal of biochemistry.

Surprising unreactivity of cholesterol-5,6-epoxides towards nucleophiles[S]

M. Poirot, S. Silvente-Poirot, P. de Medina, 2012, Journal of Lipid Research.

When cholesterol meets histamine, it gives rise to dendrogenin A: a tumour suppressor metabolite.

M. Poirot, S. Silvente-Poirot, 2016, Biochemical Society transactions.

Emerging concepts on the role of exosomes in lipid metabolic diseases.

M. Record, M. Poirot, S. Silvente-Poirot, 2014, Biochimie.

Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies.

M. Record, Kévin Carayon, M. Poirot, 2014, Biochimica et biophysica acta.

Exosomes as intercellular signalosomes and pharmacological effectors.

M. Record, M. Poirot, S. Silvente-Poirot, 2011, Biochemical pharmacology.

Role of the extracellular domains of the cholecystokinin receptor in agonist binding.

S. Silvente-Poirot, S. Wank, C. Escrieut, 1998, Molecular pharmacology.

Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study

P. Marquet, F. Dalenc, M. Poirot, 2017, The Journal of Steroid Biochemistry and Molecular Biology.

Dendrogenin A drives LXR to trigger lethal autophagy in cancers

M. Record, Kévin Carayon, L. Ligat, 2017, Nature Communications.

Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism

B. Sola, M. Poirot, S. Silvente-Poirot, 2013, Oncotarget.

Cholesterol metabolism and resistance to tamoxifen.

R. Weichselbaum, M. Poirot, S. Silvente-Poirot, 2012, Current opinion in pharmacology.

The 5,6‐epoxycholesterol metabolic pathway in breast cancer: Emergence of new pharmacological targets

M. Poirot, S. Silvente-Poirot, P. de Medina, 2020, British journal of pharmacology.

From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metabolite.

M. Record, M. Poirot, S. Silvente-Poirot, 2016, Biochimie.

Vitamin E: an overview

R. Owen, M. Poirot, S. Silvente-Poirot, 2020 .

Oxysterols are potential physiological regulators of ageing

M. Poirot, S. Silvente-Poirot, P. Medina, 2022, Ageing Research Reviews.

Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy

P. Brousset, Y. Hannun, M. Record, 2021, Cancer Immunology Research.

The Effects of Cholesterol-Derived Oncometabolites on Nuclear Receptor Function in Cancer.

F. Dalenc, M. Poirot, S. Silvente-Poirot, 2018, Cancer research.

Ligand-dependent transcriptional induction of lethal autophagy: A new perspective for cancer treatment

M. Poirot, S. Silvente-Poirot, Gregory Segala, 2018, Autophagy.

The novel steroidal alkaloids dendrogenin A and B promote proliferation of adult neural stem cells.

S. Khalifa, H. El‐Seedi, M. Poirot, 2014, Biochemical and biophysical research communications.

Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor

M. Lacroix-Triki, M. Record, P. Rochaix, 2017, Proceedings of the National Academy of Sciences of the United States of America.

One step synthesis of 6-oxo-cholestan-3β,5α-diol.

M. Poirot, S. Silvente-Poirot, Maud Voisin, 2014, Biochemical and biophysical research communications.

Extracellular vesicles: lipids as key components of their biogenesis and functions

M. Record, M. Wakelam, M. Poirot, 2018, Journal of Lipid Research.

The Prototypical Inhibitor of Cholesterol Esterification, Sah 58-035 [3-[Decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], Is an Agonist of Estrogen Receptors

G. Favre, M. Poirot, S. Silvente-Poirot, 2006, Journal of Pharmacology and Experimental Therapeutics.

An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management

J. Giesy, M. Poirot, S. Silvente-Poirot, 2023, Journal of personalized medicine.

Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation

M. Poirot, S. Silvente-Poirot, P. de Medina, 2009, Autophagy.

Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism

Isabelle Fourquaux, Justine Bertrand-Michel, M. Record, 2008, Molecular Cancer Therapeutics.

Met-195 of the Cholecystokinin-A Receptor Interacts with the Sulfated Tyrosine of Cholecystokinin and Is Crucial for Receptor Transition to High Affinity State*

B. Maigret, N. Vaysse, S. Silvente-Poirot, 1998, The Journal of Biological Chemistry.

A Segment of Five Amino Acids in the Second Extracellular Loop of the Cholecystokinin-B Receptor Is Essential for Selectivity of the Peptide Agonist Gastrin*

S. Silvente-Poirot, S. Wank, 1996, The Journal of Biological Chemistry.

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Sara W. Bird, Erinna F. Lee, Michael D. Kim, 2016 .

Insights into the Cholecystokinin 2 Receptor Binding Site and Processes of Activation

G. Favre, M. Poirot, S. Silvente-Poirot, 2006, Molecular Pharmacology.

Is cholesterol a risk factor for breast cancer incidence and outcome?

F. Guéraud, T. Durand, M. Poirot, 2023, The Journal of Steroid Biochemistry and Molecular Biology.

Targeting NR1H/liver X receptor with dendrogenin A differentiates tumor cells to activate a new secretory pathway releasing immunogenic anti-tumor vesicles enriched in LC3-II-associated exosomes

M. Record, M. Poirot, S. Silvente-Poirot, 2022, Autophagy.

Mutation of Asn-391 within the conserved NPXXY motif of the cholecystokinin B receptor abolishes Gq protein activation without affecting its association with the receptor.

A. Kowalski-Chauvel, L. Pradayrol, N. Vaysse, 2000, The Journal of biological chemistry.

In vitro and In vivo oxidation and cleavage products of tocols: From chemical tuners to “VitaminEome” therapeutics. A narrative review

M. Poirot, S. Silvente-Poirot, L. Hajji, 2022, Food Bioscience.

Chemical Synthesis and Biochemical Properties of Cholestane-5α,6β-diol-3-sulfonate, A Non-hydrolysable Analogue of cholestane-5α,6β-diol-3β-sulfate

M. Poirot, S. Silvente-Poirot, B. Payre, 2023, The Journal of Steroid Biochemistry and Molecular Biology.

Improvement of 5,6α-epoxycholesterol, 5,6β-epoxycholesterol, cholestane-3β,5α,6β-triol and 6-oxo-cholestan-3β,5α-diol recovery for quantification by GC/MS.

M. Poirot, S. Silvente-Poirot, J. Leignadier, 2017, Chemistry and physics of lipids.

Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor

M. Lacroix-Triki, M. Record, P. Rochaix, 2017, Proceedings of the National Academy of Sciences.

Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies.

Luis Moroder, Bernard Maigret, Céline Galés, 2003, Molecular pharmacology.